Plain English Summary
Background and study aims
All patients diagnosed with rectal cancer have an MRI to determine whether the rectal cancer is early or advanced. Patients with early cancer proceed directly to surgery and based on tests done on the rectal cancer after surgery may require chemotherapy and/or radiation. Patients with advanced rectal cancer have chemotherapy and radiation before surgery and chemotherapy after surgery. The advantage of having chemotherapy and radiation before surgery is that it decreases the risk of the rectal cancer coming back. However, the disadvantage of having chemotherapy and radiation before surgery is that it does not improve overall survival (i.e. chance of cure) and leads to slightly poorer bowel and sexual function than when surgery is performed alone. Therefore, the results of the MRI are very important because they determine whether the rectal cancer is early or advanced and whether or not chemotherapy and radiation will be required before surgery.
Currently, the standard criteria used on MRI to determine whether the rectal cancer is early or locally advanced are depth of tumour invasion into the bowel wall (T-category) and involvement of lymph nodes (N-category). Recently, two studies from Europe have used new MRI criteria using the predicted resection margin (rim of normal tissue surrounding the tumour) to determine whether the rectal cancer is early or locally advanced. These studies showed that when using this new MRI criteria, more rectal cancers were classified as early and, therefore, fewer patients required chemotherapy and radiation before surgery. These studies showed that even though fewer patients received chemotherapy and radiation before surgery, the risk of the rectal cancer coming back was low. Since these studies were done in different countries, the purpose of this study is to assess whether the new MRI criteria is safe to use in Canada.
Who can participate?
Patients aged 18 years or older with rectal cancer.
What does the study involve?
Participants will receive the exact same tests and surgery that they would receive if they were not participating in this study. However, instead of using the current selection criteria to make a treatment recommendation about having chemotherapy and radiation before surgery, a less strict selection criteria will be used to decide whether or not to recommend chemotherapy and radiation. This means that by participating in the study, participants will be less likely to receive chemotherapy and radiation than if they were not participating in the study. The surgical procedure they receive will be the same regardless of whether or not they participate in this study, as will their care following surgery. The portion of the rectum (including the tumour) that has been removed will be examined in the usual way by the pathologist.
What are the possible benefits and risks of participating?
The potential benefit of not undergoing chemotherapy and radiation before surgery is that the length of treatment will be about 2-3 months shorter and participants will have better bowel and sexual function with surgery alone than if they have chemotherapy and radiation before surgery. Although two studies have shown that using the new MRI criteria is safe and has the same local recurrence rate as standard MRI criteria (which is around 7.5%), we are not 100% certain of this. Therefore, while we do not think that the local recurrence rate will be more than 7.5% using the new MRI criteria, there is a chance that the local recurrence rate could be as high as 15%, which is two times higher than our standard approach.
Where is the study run from?
Fifteen hospitals from across Canada will be participating in this study.
When is the study starting and how long is it expected to run for?
The study will start in September 2014 and end in September 2016.
Who is funding the study?
Mount Sinai Hospital (Canada).
Who is the main contact?
Dr Erin Kennedy
Trial website
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
N/A
Study information
Scientific title
A Phase II prospective cohort study to assess the safety of a new MRI approach to pre-operatively stage rectal cancer and guide treatment
Acronym
Study hypothesis
It is expected that the results of this study will show that this new approach to the selection of rectal cancer patients for pre-operative chemoradiotherapy using MRI to predict the circumferential resection margin will be safe.
Ethics approval
Mount Sinai Hospital Research Ethics Board, 08/01/2014, 13-0147A
Study design
Phase II prospective cohort study
Primary study design
Interventional
Secondary study design
Cohort study
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
N/A
Condition
Rectal cancer
Intervention
Participants (i.e., rectal cancer patients) in this study will receive the exact same tests and surgery that they would receive if they were not participating in this study. However, instead of using the current or more strict selection criteria to make a treatment recommendation about pre-operative chemoradiotherapy (preCRT), a more refined or less strict selection criteria will be used to decide whether or not to recommend preCRT. This means that by participating in the study, participants will be less likely to receive preCRT than if they were not participating in the study. The surgical procedure they receive will be the same regardless of whether or not they participate in this study, as will their care following surgery. The portion of the rectum (including the tumour) that has been removed will be examined in the usual way by the pathologist.
Intervention type
Other
Phase
Phase II
Drug names
Primary outcome measures
The primary outcome for the study will be the safety of this new MRI approach in terms of positive circumferential resection margin (CRM) in the pathological specimen. The positive CRM rate is a well-established and accepted surrogate measure of local recurrence and the new MRI criteria will be considered safe if a positive CRM rate of less than 5% is achieved.
Secondary outcome measures
N/A
Overall trial start date
01/09/2014
Overall trial end date
01/09/2016
Reason abandoned
Eligibility
Participant inclusion criteria
1. Diagnosis of rectal cancer (0-15 cm) from the anal verge on endoscopy and/or proximal extent of tumour at or below the sacral promontory on CT or MRI
2. 18 years or older
3. Able to provide written consent
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
A total of 75 patients from all participating centres across Canada
Participant exclusion criteria
1. Planned abdomino-perineal resection (APR) based on pre-treatment assessment
2. Planned local excision based on pre-treatment assessment
3. Suspicious extramesorectal lymph nodes on MRI
4. Unable to undergo MRI due to claustrophobia, metal fragments, implanted metal devices or contrast allergy
5. Metastatic disease (including extramesorectal lymph nodes, carcinomatosis, liver, lung)
6. Pregnancy
7. Inflammatory bowel disease
8. Previous pelvic radiation
9. More than one primary tumour
Recruitment start date
01/09/2014
Recruitment end date
01/09/2016
Locations
Countries of recruitment
Canada
Trial participating centre
Mount Sinai Hospital
Toronto
M5G 1X5
Canada
Sponsor information
Organisation
Mount Sinai Hospital (Canada)
Sponsor details
Toronto General Hospital
NCSB LC-412
585 University Avenue
Toronto
M5G N2N
Canada
Sponsor type
Hospital/treatment centre
Website
Funders
Funder type
Hospital/treatment centre
Funder name
Mount Sinai Hospital (Canada), University Health Network Academic Medical Organization Innovation Fund
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Results - basic reporting
Publication summary